tiprankstipranks
Trending News
More News >
Rhythm Biosciences Ltd. (AU:RHY)
:RHY
Australian Market
Advertisement

Rhythm Biosciences Ltd. (RHY) AI Stock Analysis

Compare
6 Followers

Top Page

AU

Rhythm Biosciences Ltd.

(Sydney:RHY)

Rating:50Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Rhythm Biosciences Ltd.'s overall stock score is primarily impacted by its challenging financial performance, characterized by negative margins and liquidity issues. While the technical analysis shows some short-term momentum, the longer-term outlook remains bearish. Valuation concerns further weigh on the score due to a negative P/E ratio and lack of dividends.

Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)

Rhythm Biosciences Ltd. Business Overview & Revenue Model

Company DescriptionRhythm Biosciences Ltd. (RHY) is an Australian-based medical diagnostics company specializing in the development and commercialization of innovative testing solutions for the early detection and monitoring of cancer. The company's core product, ColoSTAT, is a non-invasive diagnostic test designed to detect colorectal cancer at an early stage, providing a simpler and more accessible screening alternative to traditional methods. Rhythm Biosciences focuses on leveraging cutting-edge technology to improve patient outcomes and expand its presence in the global healthcare market.
How the Company Makes MoneyRhythm Biosciences makes money primarily through the commercialization of its ColoSTAT product, targeting healthcare providers, laboratories, and diagnostic centers as its main customer base. Revenue streams include direct sales of the ColoSTAT test kits and potential licensing agreements or partnerships with healthcare organizations and distributors to expand market reach. The company may also generate income through collaborations with research institutions for the development of additional diagnostic solutions. Key factors contributing to its earnings include successful market penetration, regulatory approvals, and strategic partnerships that enhance distribution and adoption of its products.

Rhythm Biosciences Ltd. Financial Statement Overview

Summary
Rhythm Biosciences Ltd. faces significant financial challenges across income, balance sheet, and cash flow verticals. Negative margins and declining revenues indicate operational difficulties, while the balance sheet shows limited leverage but decreasing equity. Cash flow metrics underscore liquidity issues, with a continued need for external financing.
Income Statement
35
Negative
Rhythm Biosciences Ltd. has experienced a declining revenue trend, with revenue dropping significantly from 2023 to 2024. The company has negative gross and net profit margins, indicating continued operational losses. EBIT and EBITDA margins are also negative, reflecting ongoing challenges in achieving profitability. Despite past revenue growth, the current financial performance suggests significant room for improvement in income generation and cost management.
Balance Sheet
45
Neutral
The balance sheet reveals a small debt-to-equity ratio, which is a positive sign of minimal leverage. However, the return on equity is negative due to continued net losses, limiting shareholder returns. The equity ratio indicates modest equity financing, but declining asset and equity values year-over-year pose risks to financial stability.
Cash Flow
40
Negative
Free cash flow remains negative, though slightly improved from the previous year, indicating cash constraints. The operating cash flow to net income ratio is negative, which suggests cash outflows exceed earnings. Continued reliance on financing activities to cover operational shortfalls highlights liquidity challenges.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.69M3.10M2.43M1.11M100.00K
Gross Profit-1.36M2.91M2.33M961.86K-41.29K
EBITDA-6.80M-11.11M-11.10M-6.46M-3.87M
Net Income-6.86M-8.22M-8.79M-6.61M-4.02M
Balance Sheet
Total Assets1.52M7.70M8.44M3.07M2.65M
Cash, Cash Equivalents and Short-Term Investments754.50K4.17M7.60M2.27M1.84M
Total Debt163.82K84.61K170.14K0.0042.44K
Total Liabilities651.54K1.82M1.07M1.36M802.85K
Stockholders Equity867.17K5.87M7.37M1.71M1.84M
Cash Flow
Free Cash Flow-6.22M-7.06M-6.24M-5.47M-2.79M
Operating Cash Flow-6.14M-6.96M-6.21M-5.40M-2.74M
Investing Cash Flow-82.28K-99.12K-27.01K-68.27K-45.53K
Financing Cash Flow2.80M3.63M11.85M5.90M-142.22K

Rhythm Biosciences Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.06
Price Trends
50DMA
0.06
Positive
100DMA
0.07
Negative
200DMA
0.08
Negative
Market Momentum
MACD
<0.01
Negative
RSI
54.31
Neutral
STOCH
69.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHY, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.31 is Neutral, neither overbought nor oversold. The STOCH value of 69.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:RHY.

Rhythm Biosciences Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AULDX
57
Neutral
AU$53.15M-51.49%80.84%57.59%
50
Neutral
AU$2.58B3.39-57.47%2.66%36.73%13.67%
AURHY
50
Neutral
AU$16.26M-71.10%76.17%
AUBDX
45
Neutral
AU$25.62M-104.23%-17.26%
AUGSS
45
Neutral
AU$89.72M-47.52%44.61%16.40%
AUIIQ
45
Neutral
AU$43.54M-39.07%26.07%0.85%
AUGTG
43
Neutral
$5.67M-181.97%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:RHY
Rhythm Biosciences Ltd.
0.06
0.00
0.00%
AU:GTG
Genetic Technologies
0.04
>-0.01
-17.02%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.07
-50.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.06
0.02
50.00%
AU:GSS
Genetic Signatures Ltd.
0.40
-0.37
-48.05%
AU:IIQ
Inoviq Ltd
0.39
-0.20
-33.90%

Rhythm Biosciences Ltd. Corporate Events

Rhythm Biosciences Launches Strategic Pilot for geneTypeTM with Australian Pathology Provider
Jul 16, 2025

Rhythm Biosciences Ltd has announced a strategic pilot program for its geneTypeTM platform in partnership with a leading Australian pathology provider. This collaboration marks the first domestic pilot since Rhythm’s acquisition of geneType and aims to expand patient access to geneTypeTM tests through established clinical pathways. The partnership is expected to facilitate the commercial growth of geneTypeTM, enhancing Rhythm’s position in the predictive cancer diagnostics industry and creating opportunities for increased revenue.

FIL Limited Increases Stake in Rhythm Biosciences
Jul 3, 2025

Rhythm Biosciences Ltd. has experienced a change in the interests of its substantial holder, FIL Limited, which has increased its voting power from 6.04% to 7.11%. This change reflects FIL’s continued investment in the company through multiple stock purchases over several months, indicating confidence in Rhythm Biosciences’ future prospects. The increase in voting power could potentially influence company decisions and strategies, impacting stakeholders and the company’s market positioning.

Rhythm Biosciences Secures $1 Million Funding to Advance Cancer Diagnostics
Jun 30, 2025

Rhythm Biosciences Ltd has secured $1 million in non-dilutive funding from Endpoints Capital, backed by its Research and Development Tax Incentive. This funding will support the company’s operations, including the commercial launch of the updated ColoSTAT® assay and expansion of the geneType™ product line. The financial boost is seen as a vote of confidence in Rhythm’s R&D efforts and is expected to accelerate the company’s progress in achieving key milestones, potentially enhancing its market position in the cancer diagnostics industry.

Rhythm Biosciences Secures NATA Accreditation, Paving Way for ColoSTAT® Launch
Jun 24, 2025

Rhythm Biosciences Ltd has successfully reinstated NATA accreditation for its geneType cancer risk assessment portfolio, following the acquisition of Genetype assets from Genetic Technologies Ltd. This milestone is pivotal for the company’s ColoSTAT® commercialisation strategy, allowing it to progress as an in-house in vitro diagnostic (IVD) and generate real-world data, essential for its global commercialization efforts.

Rhythm Biosciences Announces Leadership Transition to Drive Growth
Jun 23, 2025

Rhythm Biosciences Ltd announced a leadership transition as part of its long-term succession strategy, with Mr. Gavin Fox-Smith set to become the Chairman of the Board following Mr. Otto Buttula’s retirement at the 2025 AGM. This transition is expected to drive the company’s strategic execution and unlock further value for shareholders, as the company continues to expand its diagnostic product offerings and partnerships, positioning itself for sustainable growth in the cancer diagnostics industry.

Rhythm Biosciences Announces New Cancer Detection Products
Jun 19, 2025

Rhythm Biosciences Ltd. has announced the commercial availability of its geneType product and anticipates the launch of ColoSTAT in the second half of 2025. These products, protected by patents, are designed for easy adoption in routine laboratories and represent a significant advancement in cancer risk assessment and detection, potentially impacting the company’s market positioning and offering valuable solutions to stakeholders.

Rhythm Biosciences Unveils Enhanced Colorectal Cancer Risk Model
Jun 10, 2025

Rhythm Biosciences Ltd has announced the publication of a peer-reviewed study in PLoS One, detailing an enhanced colorectal cancer risk assessment model. This new model, an extension of the geneType™ product line, incorporates sex-specific and additional risk factors, outperforming existing models. The study, which used data from nearly 400,000 individuals in the UK Biobank, highlights the model’s superior predictive ability and its potential for commercial clinical applications. The innovation underscores Rhythm’s commitment to advancing cancer risk prediction and improving stratified screening, positioning the company as a leader in predictive diagnostics technology.

Rhythm Biosciences Issues New Shares to Bolster Cancer Detection Initiatives
Jun 2, 2025

Rhythm Biosciences Ltd announced the issuance of 483,871 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company confirmed compliance with relevant provisions of the Corporations Act and stated that there is no excluded information to disclose. This issuance supports Rhythm’s ongoing efforts to enhance its market position in the medical diagnostics industry, particularly in the early detection of colorectal cancer through its ColoSTAT® Test-Kit. The test, which measures specific protein biomarkers, offers an alternative to current screening programs and aims to reduce mortality rates and healthcare costs associated with colorectal cancer.

Rhythm Biosciences Announces New Securities Quotation on ASX
Jun 2, 2025

Rhythm Biosciences Ltd. has announced the application for quotation of 483,871 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective June 2, 2025. This move is part of previously announced transactions and could potentially enhance the company’s market presence and liquidity, impacting its operations and stakeholder interests positively.

Rhythm Biosciences Announces Investor Roadshow Presentation
Jun 2, 2025

Rhythm Biosciences Ltd. has released a presentation for an investor roadshow scheduled from June 2nd to 5th, 2025. The presentation is intended for general information purposes and cautions against reliance on forward-looking statements due to potential risks and uncertainties. This announcement underscores the company’s commitment to transparency with its stakeholders, although it highlights the inherent uncertainties in the biotechnology sector.

Rhythm Biosciences Announces Proposed Issue of Securities
May 30, 2025

Rhythm Biosciences Ltd. has announced a proposed issue of 483,871 ordinary fully paid securities, with the issue date set for June 2, 2025. This move is part of a placement or other type of issue, which could potentially enhance the company’s capital structure, providing additional resources for its operations and strategic initiatives in the biotechnology sector.

Rhythm Biosciences Advances ColoSTAT® Kit Towards Commercialization
May 25, 2025

Rhythm Biosciences Ltd has successfully completed the verification and validation of its second-generation ColoSTAT® assay Beta kits, marking a significant step towards commercialization. The optimized kits, designed for routine lab use, have demonstrated improved performance, reduced turnaround times, and cost efficiency. The company is now transitioning to the final manufacturing stage with its partner Quansys, aiming for commercial availability following further testing and accreditation. This advancement strengthens Rhythm’s position in the cancer diagnostics industry and promises to enhance colorectal cancer detection, potentially reducing mortality and healthcare costs.

Rhythm Biosciences Secures Contract for Breast Cancer Risk Study with University of Melbourne
May 15, 2025

Rhythm Biosciences Ltd has announced a 12-month contract through its subsidiary Genetype with the University of Melbourne to provide geneType™ Breast Cancer Risk assessment. This partnership aims to enhance breast cancer screening for Australian women aged 40-59 by integrating personalized risk assessment approaches, which align with national guidelines. The study will incorporate factors like family history, mammographic breast density, and polygenic risk scores, potentially setting a new standard for risk-stratified screening. This collaboration not only accelerates Genetype’s commercial growth but also strengthens its market position in predictive cancer diagnostics, offering significant implications for stakeholders by potentially improving the effectiveness of breast cancer screening and expanding the use of personalized risk models.

Rhythm Biosciences Issues New Unquoted Securities
May 2, 2025

Rhythm Biosciences Ltd. announced the issuance of 401,716 unquoted securities, specifically options expiring on March 31, 2026, with an exercise price of $0.20. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX. The move reflects the company’s ongoing strategic financial maneuvers to support its operations and growth within the biotechnology sector, potentially impacting its market positioning and stakeholder interests.

Rhythm Biosciences Announces Proposed Securities Issue
May 1, 2025

Rhythm Biosciences Ltd. announced a proposed issue of securities, specifically options expiring on March 31, 2026, with an exercise price of $0.20. This issuance, involving a total of 401,716 securities, is aimed at raising capital to support the company’s operational and strategic initiatives. The announcement reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence in the biotechnology sector.

Rhythm Biosciences Advances ColoSTAT® and Expands Product Portfolio
Apr 24, 2025

Rhythm Biosciences Ltd has announced significant progress in its ColoSTAT® Beta kits, which are in the final verification phase and preparing for clinical validation. The company has also successfully integrated the Genetype business and relaunched the geneType™ product portfolio, achieving its first commercial sales. These developments, alongside strategic management enhancements, position Rhythm Biosciences to strengthen its operations and market presence, with expectations for further milestones in the upcoming quarters.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025